FB-TW

Showing posts with label Journal of the American College of Cardiology. Show all posts
Showing posts with label Journal of the American College of Cardiology. Show all posts

Monday, April 8, 2013

HDL Particle Concentration is a Better Predictor of Coronary Heart Disease - Honigberg


HDL Particle Concentration is a Better Predictor of Coronary Heart Disease Risk than HDL Cholesterol

Robert Honigberg, MD

Several recent, high-profile clinical trial failures of experimental high density lipoprotein (HDL)-raising therapies has prompted members of the scientific and medical communities to question the prognostic value of HDL as an indicator of coronary heart disease (CHD) risk. However, new research suggests that we should update clinical guidelines with a more predictive measurement of HDL-related risk.

The study, which evaluated the independent associations of high density lipoprotein cholesterol (HDL-C) and high density lipoprotein particle (HDL-P) concentrations with CHD, suggests that HDL-P may be a more accurate indicator of cardiovascular risk than HDL-C. The findings were published in the current issue of the Journal of the American College of Cardiology.

Researchers analyzed blood samples obtained at study onset from 5,598 middle-aged men and women free of cardiovascular disease who participated in the Multi-Ethnic Study of Atherosclerosis (MESA), a prospective observational study initiated and overseen by the National Heart, Lung and Blood Institute. Participants were followed for a mean of six years for incident CHD events—including angina, heart attack, and coronary heart disease death.

The researchers concluded that baseline levels of HDL-C and HDL-P were both inversely associated with CHD events and carotid atherosclerosis in this study population. However, after adjusting each HDL measure for the other and for LDL-P, joint analysis demonstrated that the inverse relationship for CV risk persisted for HDL-P but no longer existed for HDL-C. The more consistent inverse association between cardiovascular endpoints and HDL-P has also been shown in other studies including the HPS, MR-FIT, EPIC-NORFOLK and VA-HIT trials. In the accompanying editorial, Emil deGoma and Dan Rader noted that HDL-P may be more useful to refine cardiovascular risk and to evaluate novel HDL-directed therapies.

In light of this study’s findings, it is likely that more research will be conducted which extends beyond traditional HDL-C measurement to sort out the different functional properties of HDL. We at LipoScience contend that measuring HDL-P in clinical practice can lead to better patient treatment decisions, particularly as the LDL particle number is brought under control. Obviously this is a provocative subject, and I’d love for you share your thoughts in the comment section.
==================================================================
Read the full article here.

Thursday, March 7, 2013

Heart Failure Mortality Linked to Glucose Levels - Fiore

Heart Failure Mortality Linked to Glucose Levels

 
By Kristina Fiore, Staff Writer, MedPage Today
Published: January 17, 2013
Reviewed by F. Perry Wilson, MD, MSCE; Instructor of Medicine, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner
Serum glucose measured at the time of hospital admission predicted 30-day mortality in acute heart failure patients, researchers reported.
.
.
.

“Our results are consistent with basic and clinical science data linking an elevated blood glucose level with myocardial injury, impaired myocardial performance, arrhythmia, and risk of ventricular remodeling,” they wrote.

Elevated glucose has also been associated with worse outcomes for patients with stroke and other critical illnesses, the researchers said, but its short-term prognostic impact in acute heart failure isn’t known.

Mebazaa and colleagues analyzed data from a multi-national cohort of 6,212 acute heart failure patients who had a mean age of 72, and 41% of whom had a previous diagnosis of diabetes.

The mean blood glucose concentration on arrival at the hospital was 7.5 mmol/L (135 mg/dL), and after 30 days, 10% of the patients had died.

Mebazaa and colleagues found that patients who died had a significantly higher median blood glucose concentration at admission compared with survivors ...

The risk between blood sugar levels and 30-day mortality was consistent across all subgroups of patients, the researchers reported,
.
.
.

They also emphasized that the relationship between blood sugar and death was seen in patients both with and without a previous diagnosis of diabetes.

In sensitivity analyses, adjusting for factors such as left ventricular ejection fraction (LVEF) and plasma natriuretic peptides, as well as excluding patients from the largest cohort, didn’t significantly alter any of the findings.
.
.
.
The researchers said it was not clear whether elevated blood sugar in acute heart failure is “a marker for risk or a mediator of adverse outcomes” — but since serum glucose is “widely measured, easily interpreted, and inexpensive to measure,” using it in risk assessment is “worthy of consideration.”
The study was limited by a lack of data on glycated hemoglobin (HbA1c) at admission and by the absence of serial measurements of glucose during the hospital stay.

Further work is needed to better understand the pathophysiology and complete trajectory of hyperglycemia in acute heart failure, they concluded.
==============================================================
Read the complete article here.

Download Complimentary Source PDF



Monday, February 28, 2011

Coronary Artery Calcium (CAC) Scanning

From: http://www.theheart.org/

Texas Heart Attack Prevention legislation "premature," expert says

February 28, 2011 |                                 Shelley Wood
Dallas, TX - The quiet passage of 2009's Texas Heart Attack Prevention Bill will have ramifications that will "ring loudly" for public health, predicts a Commentary published in the Archives of Internal Medicine this week [1].
As reported in-depth by heartwire, the bill, known as HB 1290, grew out of a bold, unprecedented proposal from the Society for Heart Attack Prevention and Education (SHAPE, a group with no ties to either of the main cardiology professional societies) and mandates insurance coverage at regular intervals for coronary artery calcium (CAC) scanning and carotid ultrasound in the state of Texas. A new bill modeled on the Texas legislation is also poised for consideration in Florida in the coming weeks.
.
.
.
Conspicuously absent, he notes, was any kind of expert testimony from the American Heart Association or American College of Cardiology. As previously reported by heartwire, both societies stayed mum on SHAPE, drawing criticism for their silence, although the ACC told heartwire that their Texas ACC chapter "officially supported this piece of legislation and [was] glad to see that it has passed."
For many prominent cardiologists who were involved in SHAPE—most of whom don't hail from Texas—the bill's passing in some ways validates the work of their organization. Several SHAPE members have told heartwire that they believe their aggressive support for population-based screening fills a void that the professional societies have been too slow to move into.
.
.
.
...that the State of Florida is poised to consider Senate Bill 360, inspired by the Texas bill, which would require insurance reimbursement for up to $200 for CAC and CIMT screening. The bill, sponsored by Florida State Senator Mike Fasano, has been submitted and assigned to committee; the Florida legislature begins its sessions tomorrow.
.
.
.
Asked what he thought about a screening bill now being considered in Florida, Khera said, "In some ways, I can understand why: this is the number-one cause of death, and I certainly appreciate that legislators want to do something, because people are dying from heart disease."
=================================
Read the full article here:

Wednesday, August 12, 2009

The diet–heart hypothesis: a critique

An article under VIEWPOINT AND COMMENTARY in the Journal of the American College of Cardiology (JACC) titled "The diet–heart hypothesis: a critique" by Sylvan Lee Weinberg, MD, states the following in the final paragraph. Please read the complete article here.

"A balanced appraisal of the diet–heart hypothesis must recognize the unintended and unanticipated role that the LF-HCarb diet may well have played in the current epidemic of obesity, abnormal lipid patterns, type II diabetes, and the metabolic syndrome. Defense of the LF-HCarb diet, because it conforms to current traditional dietary recommendations, by appealing to the authority of its prestigious medical and institutional sponsors or by ignoring an increasingly critical medical literature, is no longer tenable. The categoric rejection of experience and an increasingly favorable medical literature, though still not conclusive, which suggests that the much-maligned LCarb-HP diet may have a favorable impact on obesity, lipid patterns, type II diabetes, and the metabolic syndrome, is also no longer tenable."


Thursday, August 30, 2007

Cholesterol lowering statin drugs and Cancer!

Today I came across an article in Medical News Today (http://www.medicalnewstoday.com/) in the section under the Main Category: Cholesterol News which re-opened my eyes to the scary connection between statin drugs and cancer. I've linked to the full article under Credible Evidence.

The first paragraph of this article states the following:


"Statins, a type of LDL cholesterol-lowering drug, were recently shown to have a significant, positive association with newly diagnosed cancer cases. When newly diagnosed cancer cases were correlated with cholesterol reduction, a disturbing significant correspondence was found, and recently published as, "Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer, by Alsheikh-Ali, et al., in Journal of the American College of Cardiology (Vol. 50, No. 5, 2007, pages 409-418)."

So I ask "Would you rather die of a Heart Attack or from Cancer?" Of course if we had our druthers we'd likely all say 'NEITHER' Right? Well think about it for a moment then answer.

And If I was a betting man I'd bet this won't make the big time news.

Furthermore it's not even new news.


The PROSPER trial found a 25% increase in newly diagnosed cancers among elderly individuals treated with pravastatin (Pravachol). There were 24 more deaths from cancer to more than offset the 20 fewer deaths due to coronary heart disease. This had also been observed in animal tests earlier with one of the highest increases observed in the gastrointestinal cancers. And who should be suprised that the PROSPER authors dismissed these findings by referring to pooled analysis which showed no statistically significant difference in cancer incidence between placebo and statin groups. The PROSPER trial did not even include skin cancer. Two others did however, the Scandinavian Simvastatin Survival Study (4S) and the HPS simvastatin trial. They both noted an increase in skin cancer. And in the CARE trial 12 women taking pravastatin developed breast cancer whereas only one in the placebo group developed breast cancer.

Other quotes from the Medical News Today article :


"Following the adage, "lower is better," intensive LDL cholesterol lowering has been practiced by physicians on their patients throughout America since 1987, with Lovastatin and more recently with a new generation of statins."

"With statin use, the increase in cancer deaths offset (counteract) the lower cardiac mortality associated with lower cholesterol, resulting in a neutral effect of overall mortality. TRANSLATION: With statins, you don't die of a heart attack, instead, you die of cancer."

Well now that you've thought about it would you die of a heart attack or of cancer?

A side note that makes this a bit personal for me:
  • I was on cholesterol lowering statins for roughly 20 years beginning in the mid 1980s. I finally discontinues taking statins sometime in 2004

  • In 1994 (with low cholesterol) I had a heart attack resulting in open heart surgery.

  • P.S. Five subsequent heart attacks (most recent Jan 31, 2012), three requiring stents - all while having well below 'their recommended' serum cholesterol readings. (added this item Oct 8, 2007)

  • In 2003 I had a fist sized gastrointestinal cancerous tumor removed along with about 9 inches of my small intestine.

  • I've had one basal cell carcinoma (skin cancer) surgically removed about 3 years ago.


  • I personally have no data to tie these events in my life together.


  • I feel good now - like none of the above had happened. It almost seems surreal. But I've had five subsequent heart attacks - three with stents and there is some possibility that the cancer could reappear.

Something is going to get me sooner or later.

What will it be?
I'd pick the heart attack over cancer.


Am I worried? NO!

Because I believe the words of this hymn:


I know not why God's wondrous grace to me he hath made known,
nor why, unworthy, Christ in love redeemed me for his own.

But I know whom I have believed, and am persuaded that he is able
to keep that which I've committed unto him against that day.

I know not how this saving faith to me he did impart,
nor how believing in his word wrought peace within my heart.

I know not how the Spirit moves, convincing us of sin,
revealing Jesus through the word, creating faith in him.

I know not when my Lord may come, at night or noonday fair,
nor if I walk the vale with him, or meet him in the air.

But I know whom I have believed, and am persuaded that he is able to keep that which I've committed unto him against that day.

Saturday, August 18, 2007

Messed up food pyramid is ruining our health!

I've linked to the article in the Journal of American Physicians and Surgeons under Credible Evidence but here's a quote from the abstract and the conclusion of the article with bold highlighting added by myself.

ABSTRACT
The USDA-sponsored Dietary Guidelines for Americans (DGA) and its Food Guide Pyramid are nutritionally and biochemically unsound. The DGA was nevertheless accepted wholeheartedly by nutrition authorities, who took Ancel Keys as their guiding spirit and his lipid hypothesis their mantra. They radically changed the food habits of tens of millions of Americans in a massive human experiment that has gone awry. Much evidence suggests that the current epidemics of cardiovascular diseases,

Conclusion
It is no secret that the lipid hypothesis, now dogma, is facing a serious challenge. America's long dietary experiment with the lowfat, high-carbohydrate diet has failed. Today, there is little doubt that there is a clear temporal association between the "hearthealthy" diet and the current, growing epidemics of cardiovascular disease, obesity, and type-2 diabetes. Many scientific papers and books support this association and explain exactly how and why the low-fat, high-carbohydrate diet causes these diseases.

Long-held beliefs that animal fat is the cause of cardiovascular disease and that grain products are the staff of life will not be relinquished without a struggle. The articles and comments widely circulated in the public press, exemplified by the denigration of the "low carb" diet and its author, the late Dr. Atkins, are evidence of this struggle.

Hope for a solution may well lie with physicians and nutritionists schooled in the biochemistry of nutrientmetabolism and open to revisiting past dogmas. As Dr. Sylvan LeeWeinberg, past president of the American College of Cardiology, states in his insightful and courageous critique of the validity of the dietheart hypothesis:

"Defense of the LF-Hcarb[low-fat, high-carbohydrate] diet, because it conforms to current traditional dietary recommendations by appealing to the authority of its prestigious medical and institutional sponsors, or by ignoring an increasingly critical medical literature, is no longer tenable."

I hope you will consider reading the whole article at: http://www.jpands.org/vol9no4/ottoboni.pdf